

Ref: ACI/D23/2882

Terms of reference

Innovation Executive Strategic Committee (LHDs/SHNs)

ACI Chief Executive		
Chair		
Lea Kirkwood, Director STEP, ACI		
Ongoing – commencing June 2023		
ACI team members		
By consensus during meeting	Date	July 6, 2023
July 5, 2024		
Review membership and Terms of Reference annually		
Decision making Consensus achieved via quorum		
	Chair Lea Kirkwood, Director STEP, ACI Ongoing – commencing June 2023 ACI team members By consensus during meeting July 5, 2024 Review membership and Terms of Refe	Chair Lea Kirkwood, Director STEP, ACI Ongoing – commencing June 2023 ACI team members By consensus during meeting Date July 5, 2024 Review membership and Terms of Reference are

Background

The Innovation Executive Strategic Committee Local Health Districts/ Speciality Health Networks (LHDs/SHNs), has been established by the Agency for Clinical Innovation (ACI), bringing together executive leads of innovation from LHDs and SHNs. An inaugural meeting validated the need to form an ongoing platform for connection related to the state-wide strategic direction on Research and innovation.

Purpose

The purpose of the Innovation Executive Strategic Committee (LHDs/SHNs) is to foster strategic collaborations among the ACI, and LHDs and SHNs in driving innovation as part of the system reform agenda in NSW Future Health strategy. This committee will also serve as a conduit for informing the Division for Clinical Innovation and Research, driving collective impact across larger public health organizations.

Responsibilities and functions

The committee will have the following responsibilities:

- Identification of common innovation priorities and collaboration opportunities: The committee will
 work towards identifying areas of common interest and innovation priorities that resonate across
 the LHDs and SHNs. By promoting collaboration and knowledge exchange, the committee aim to
 harness the collective potential of these entities for the advancement of healthcare delivery
- Strategic approach to overcoming barriers: The committee will adopt a strategic approach to address and manage barriers to innovation through analysis and consultation
- Recognition of enablers and best practices: As part of the strategic endeavours, the committee will assess and recognize the exemplary practices within each LHD. By identifying the strengths

Terms of reference 3 April 2020

- and successful initiatives of individual entities, the committee will seek to collectively learn, adapt, and disseminate these best practices throughout the committee
- Undertaking transformative initiatives: The network will actively engage in transformative projects and initiatives that have the potential to revolutionize the healthcare landscape. By leveraging the collective expertise and resources available within the member organizations, the network will aim to drive innovation, improve outcomes, and create positive impacts on the health and wellbeing of our communities
- The committee will serve as a pivotal conduit, fostering connections and collaboration with key partners in the field of innovation. This includes working closely with the Division for Clinical Innovation and Research to provide feedback and assistance in implementation of the strategies

Frequency of meetings

Quarterly

Reporting committees

The Committee will connect with and leverage the Health Precincts Community of Practice and not duplicate the purpose

Method of evaluation

The committee will assess its ability to meet its stated purpose and the progress on that purpose as part of a review once per annum

Quorum

- 50% of membership plus 1
- Where the meeting does not reach a quorum, recommendations will be circulated to all members and confirmed in the next meeting